🟢 Actively Hiring · 15d ago ⏳ Closes in 75 days 🇺🇸 US Corridor 🛡️ US Work Authorization 🏢 FULL_TIME

Medical Director, US

🏢 Alnylam Pharmaceuticals · 📍 United States · 🕒 Oct 31, 2026 · Ref: OP-VERIF-A299C0B7
Benchmark Compensation (Annual Base)
Salary Disclosed on Application
Full Benefits Package
Apply Directly →
🛡️ Career Integrity & Compliance Audit
✓ Verified Opening

This opening is authenticated by Www2. We enforce strict salary disclosure and guarantee zero processing or placement charges.

Employer Registration US State corporate entity
Wage Standards US DOL Fair Labor Standards Act
Applicant Protections 100% Free direct candidate application
SPONSORED CAREER ADVISORY AD

Position Overview & Specifications

Overview

We are seeking an experienced Medical Director to join our dynamic team in the United States, focusing on the Transthyretin (TTR) Cardiomyopathy indication. This pivotal role will drive the strategy and execution of comprehensive medical plans in the US, leveraging deep expertise in cardiology, especially within the TTR Cardiomyopathy space. The ideal candidate will serve as the organization's expert, ensuring the seamless execution of plans through our field medical team and collaborating closely with cross-functional partners to advance patient care and support healthcare professionals in the management of TTR Cardiomyopathy.

Key Responsibilities

Lead the development and implementation of strategic medical affairs plans for the TTR Cardiomyopathy indication in the US, ensuring alignment with global strategies. Serve as the primary medical expert on TTR Cardiomyopathy within the organization, providing guidance and insights to various cross functional teams. Ensure the execution of strategic plans through the field medical organization, facilitating knowledge exchange and supporting healthcare professionals. Collaborate with clinical development teams to inform and support clinical trials and research initiatives related to TTR Cardiomyopathy. Engage with key opinion leaders, patient advocacy groups, and professional societies to foster relationships and enhance the understanding of TTR Cardiomyopathy management. Oversee the development and dissemination of medical and scientific information, including publications, educational materials, and presentations at scientific conferences. Monitor and analyze scientific literature, competitive intelligence, and regulatory developments in the field of cardiology, particularly TTR Cardiomyopathy, to inform strategic direction and innovation. Ensure compliance with all regulatory, ethical, and professional guidelines in the conduct of medical affairs activities.

Qualifications

Advanced degree (PharmD, PhD, MD) with strong preference for candidates with specialization in cardiology. Demonstrated expertise in the cardiology therapeutic area, with preferred experience in the TTR Cardiomyopathy space. Minimum of 5 years of experience in medical affairs within the pharmaceutical or biotech industry, including experience in field medical roles and strategy development. Proven ability to develop and execute medical strategies and effectively communicate complex scientific information to diverse audiences. Strong leadership skills, with the ability to mentor and guide a field medical team. Excellent interpersonal, communication, and collaboration skills, with the ability to engage effectively with internal and external stakeholders. Solid understanding of clinical research, drug development processes, and regulatory environments. Ability to travel as needed to fulfill job responsibilities.

About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.

Our culture: Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we’ve been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine’s Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK – among others.

At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law.
INTERNATIONAL TALENT PLACEMENT NETWORK SPONSORED

Ready to Apply for this Opportunity?

Submit your candidate profile directly. No intermediary fees, no recruiter lock-in.

Continue to Application → Browse More US Jobs

Similar Verified Career Openings